Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“PhRMA Act” introduced in House

Executive Summary

Pharmaceutical company CEOs would be required to annually attest that all evidence of serious adverse events for a drug has been disclosed to HHS under the Pharmaceutical Research & Manufacturers Accountability Act. Introduced by Reps. Pete Stark (D-Calif.) and Marion Berry (D-Ark.) on Feb. 16, the "PhRMA Act" (HR 870) would authorize jail time and fines for CEOs and other executives for "knowing concealment...of evidence of a serious adverse drug experience." The bill also would authorize imposition of fines if post-marketing studies are not completed in a specified time period...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS045446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel